Medpace is proud to have once again been recognized with 2022 CRO Leadership Awards from Clinical Leader and Life Science Leader magazine, receiving five awards across all categories including Capabilities, Compatibility, Expertise, Quality, and Reliability; across all three groups of respondents (Big Pharma, Small Pharma, and Overall (combined Big and Small Pharma)). Medpace was also recognized with individual attribute awards including Data Quality, Meeting Project Timelines, Operational Excellence, and Responsiveness.
For the 2022 CRO Leadership Awards, Clinical Leader and Life Science Leader have once again teamed up with Industry Standard Research (ISR) to conduct the study and determine the award recipients. 50 contract research organizations were assessed on 20+ performance metrics in ISR’s annual CRO Quality Benchmarking survey to determine the CROs that meet or exceed their customers’ expectations in the categories of Capabilities, Compatibility, Expertise, Quality and Reliability. Medpace received recognition across all five categories.
Survey respondents were selected from biopharmaceutical companies of all sizes, vetted for CRO decision making authority, and were asked to evaluate only companies they had worked with on an outsourced project in the past 18 months to ensure the data behind the awards are driven by first-hand experience with the CROs being evaluated.
“ISR’s stringent screening process ensures that only highly qualified industry decision-makers participate in our CRO benchmarking market research” said Kevin Olson, CEO of Industry Standard Research. “This is paramount as we ask the research participants to provide experiential, not perceptual, feedback on their involvement with contract suppliers over the past 18 months. The data enable users of ISR’s market research to make confident business decisions based on the experiences of their industry peers.”
Medpace won a 2022 CRO Leadership Award in the following categories:
“Medpace is honored to be recognized across all categories for leadership in our industry,” commented Jesse Geiger, President, Medpace. “Our organization is celebrating 30 years of advancing clinical development this year, and this recognition is a testament to the quality and consistency of our high-science approach, cross-functional, collaborative teams of experts, and track record of seamless execution. We’re proud of what we’ve accomplished over the last three decades and look forward to continuing to exceed our sponsors’ expectations.”
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 4,700 people across 41 countries.